Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 8 for:    "Encephalitis" | "Anti-HIV Agents"

Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03969550
Recruitment Status : Completed
First Posted : May 31, 2019
Last Update Posted : May 31, 2019
Sponsor:
Information provided by (Responsible Party):
Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary:

Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial.

The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.


Condition or disease Intervention/treatment
AIDS Progressive Multifocal Leucoencephalopathy (PML) Other: Measure of overall survival

Layout table for study information
Study Type : Observational
Actual Enrollment : 34 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?
Actual Study Start Date : January 2008
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: Measure of overall survival
    Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.


Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 8 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with AR-PML, exposed or not to maraviroc, as part of combined antiretroviral treatment (cART).
Criteria

Inclusion Criteria:

  • Patients with AR-PML
  • Diagnosed between January 2008 and December 2015
  • Followed in one of the four University Hospitals' Infectious Diseases Departments

Exclusion Criteria:


Layout table for additonal information
Responsible Party: Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier: NCT03969550     History of Changes
Other Study ID Numbers: 29305436
First Posted: May 31, 2019    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fondation Ophtalmologique Adolphe de Rothschild:
Maraviroc
John Cunningham virus (JCV)
Immune reconstitution inflammatory syndrome (IRIS)
Combined antiretroviral treatment (cART)
Overall survival (OS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Encephalitis, Viral
Infectious Encephalitis
Encephalitis
Anti-HIV Agents
Leukoencephalopathy, Progressive Multifocal
Leukoencephalopathies
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Viral Diseases
Virus Diseases
Polyomavirus Infections
DNA Virus Infections
Slow Virus Diseases
Central Nervous System Infections
Demyelinating Diseases
Maraviroc
HIV Fusion Inhibitors
Viral Fusion Protein Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
CCR5 Receptor Antagonists